Streetbeat News

Price Targets

ESS

Essex Property Trust (NYSE:ESS) has received mixed analyst ratings over the past three months, with a recent trend towards bullishness. The average 12-month price target is $245.2, up from $237.00, with a high estimate of $281.00 and a low of $225.00. Analysts from Jefferies, Truist Securities, Stifel, BMO Capital, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Essex Property Trust has shown a revenue growth rate of 2.3% as of September 30, 2023, but faces challenges with a net margin below industry averages and an ROA that is also below industry standards. However, its ROE is impressive at 1.57%, and its debt-to-equity ratio is conservative at 1.13.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 7:01 pm

NCNO

Ncino (NASDAQ:NCNO) has been evaluated by 4 analysts over the last three months, with mixed opinions ranging from bullish to bearish. The average 12-month price target for NCNO is $37.25, up 6.43% from the previous target of $35.00. Analyst actions include rating changes and price target adjustments, with Piper Sandler's Brent Bracelin raising the target to $42.00 from $30.00, and Truist Securities' Terry Tillman lowering it to $37.00 from $40.00. Ncino's financial performance shows a revenue growth of 15.81%, a net margin of -13.43%, an ROE of -1.59%, an ROA of -1.27%, and a low debt-to-equity ratio of 0.06. The company specializes in cloud-based software for financial institutions and generates most of its revenue from subscription services in the United States.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 7:00 pm

SHW

Sherwin-Williams (NYSE:SHW) received mixed analyst ratings in the latest quarter, with 6 analysts providing their perspectives. The average 12-month price target for SHW is $313.83, up 1.78% from the previous target. Analysts from Argus Research, Goldman Sachs, Citigroup, JP Morgan, RBC Capital, and B of A Securities have updated their ratings and price targets, reflecting changes in market dynamics and company performance. Sherwin-Williams is a leading architectural paint provider in the U.S. with strong financial indicators such as revenue growth, net margin, ROE, and ROA, but faces challenges in debt management with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 7:00 pm

SQM

Sociedad Quimica Y Minera (NYSE:SQM) was analyzed by 7 analysts, showing a mix of sentiments with 5 somewhat bullish, 1 indifferent, and 1 somewhat bearish. The average 12-month price target is now $70.21, down from $80.00, with a high estimate of $84.00 and a low of $54.50. Analysts from firms including Scotiabank, Goldman Sachs, JP Morgan, BMO Capital, and B of A Securities have adjusted their ratings and price targets. SQM's financial performance shows a -37.79% decline in revenue growth, a high net margin of 26.05%, an ROE of 9.44%, an ROA of 4.45%, and a debt-to-equity ratio of 0.7.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 7:00 pm

WFC

In the past three months, 7 analysts have published diverse ratings on Wells Fargo (NYSE:WFC), with recent updates showing a more bullish outlook. The average 12-month price target is now $54.58, up from $50.00. Analysts from firms like Barclays and Morgan Stanley have raised their price targets, reflecting positive sentiment. Wells Fargo's financial performance shows strong net margin and ROE, with a revenue growth of 6.6% as of September 30, 2023, but trails behind the Financials sector average growth rate.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 7:00 pm

LBPH

UCBJF

UCBJY

Longboard Pharmaceuticals Inc (NASDAQ:LBPH) released positive topline data from the PACIFIC Phase 1b/2a study for its anti-seizure candidate bexicaserin, showing a median 53% reduction in seizures. Cantor Fitzgerald raised LBPH's price target from $35 to $55 and maintained an overweight rating, citing the drug's potential to achieve over $1 billion in peak sales. LBPH shares surged 222.60% to $19.45 following the news.

Portfolio Pulse from Vandana Singh

January 02, 2024 | 6:55 pm

BTCUSD

Matrixport's report suggests Bitcoin could reach $50,000 by January 2024, driven by a high funding rate of 66.1% and a potential spot Bitcoin ETF approval. Bitcoin's price has surged, hitting $45,000 for the first time in 20 months. The report also notes that Bitcoin's halving event in April 2024 and the U.S. presidential election year could further boost its price, with a potential to hit $125,000 by July 2023.

Portfolio Pulse from Khyathi Dalal

January 02, 2024 | 6:52 pm

VNRX

EF Hutton analyst Tim Moore has reiterated a Buy rating on VolitionRX (AMEX:VNRX) and maintained a price target of $4.5 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 6:34 pm

VYGR

Wells Fargo analyst Yanan Zhu has upgraded Voyager Therapeutics (VYGR) from Equal-Weight to Overweight and increased the price target from $9 to $14.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 6:27 pm

CORT

HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a Buy rating on Corcept Therapeutics (NASDAQ:CORT) but has reduced the price target from $34 to $28.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 6:21 pm